Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Syndros save search
American CryoStem Announces Patient Treatment Status for its Phase I Clinical Trial for Post-Concussion Syndrome (PCS)
Published: 2022-03-04 (Crawled : 12:00) - biospace.com/
CRYO | $0.0001 0.0% 19K
|
Information
|
| O: 0.14%
H: 0.0%
C: -11.9%
america treatment trial cryo syndros
MemorialCare Heart & Vascular Institute Participating in Global Study of CSL112 in Patients with Acute Coronary Syndrome (AEGIS-II)
Published: 2022-03-03 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
csl112 heart syndros
Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome
Published: 2022-02-28 (Crawled : 13:30) - zynerba.com
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -4.76%
H: 0.0%
C: 0.0%
phase 2 als trial syndros enroll zygel
Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome
Published: 2022-02-24 (Crawled : 20:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -4.06%
H: 0.0%
C: 0.0%
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: -3.66%
H: 8.0%
C: 6.5%
phase 2 trial therapeutics syndros enroll
Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2/3 Clinical Trial
Published: 2022-02-10 (Crawled : 13:30) - biospace.com/
DNLI | $15.98 -3.74% -3.88% 1.5M
|
Health Technology
|
| O: 1.08%
H: 3.35%
C: -2.74%
dnl310 phase 2 phase 2/3 program trial therapeutics syndros mps-ih
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome
Published: 2022-02-08 (Crawled : 12:00) - globenewswire.com
BMRA | $0.7459 -1.86% -1.89% 35K
|
Health Technology
|
| O: -0.71%
H: 2.14%
C: 0.95%
infoods treatment trial food topline results positive topline syndros
Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome
Published: 2022-02-04 (Crawled : 14:30) - biospace.com/
AVXL | News | $3.8 0.0% 2.1M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
anavex treatment anavex®2-73 trial life science phase 3 syndros rett syndrome
ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome
Published: 2022-02-01 (Crawled : 13:00) - biospace.com/
AVXL | News | $3.8 0.0% 2.1M
|
Health Technology
|
| O: 1.24%
H: 0.0%
C: -9.51%
anavex treatment trial phase 3 anavex®2-73 syndros rett syndrome
Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-01-31 (Crawled : 14:30) - biospace.com/
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 1.69%
H: 8.74%
C: 7.88%
covid-19 fast track designation treatment fda risk fast track respiratory covid grant syndros sabizabulin designation
Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome
Published: 2022-01-20 (Crawled : 13:00) - biospace.com/
ZEAL | News | $17.59 1.21% -4.21%
|
Health Technology
|
| O: -0.28%
H: 0.28%
C: -2.36%
trial phase 3 syndros enroll pharma
Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
Published: 2022-01-12 (Crawled : 13:30) - biospace.com/
ARWR | $22.33 -1.24% -1.25% 960K
|
Health Technology
|
| O: 1.71%
H: 1.17%
C: -3.83%
phase 3 syndros treatment
GeneTx and Ultragenyx Provide Preliminary Update on Phase 1/2 Clinical Study of GTX-102 in Canada and U.K. Patients with Angelman Syndrome
Published: 2022-01-05 (Crawled : 15:30) - biospace.com/
RARE | News F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 0.88%
H: 5.0%
C: -0.43%
gtx-102 phase 1 syndros
American CryoStem Announces Completion of Patient Recruitment for its Post-Concussion Syndrome (PCS) ATCELL(TM) Phase I Clinical Trial
Published: 2021-12-22 (Crawled : 08:00) - biospace.com/
CRYO | $0.0001 0.0% 19K
|
Information
|
| O: 2.3%
H: 8.55%
C: 2.31%
trial cel cryo syndros
Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome
Published: 2021-12-16 (Crawled : 09:00) - biospace.com/
ZEAL | News | $17.59 1.21% -4.21%
|
Health Technology
|
| O: -2.37%
H: 0.0%
C: -0.11%
trial phase 3 syndros enroll
Biomarker Data from Phase 1b/2 Investigator-sponsored Trial of Mereo’s Alvelestat in Bronchiolitis Obliterans Syndrome (BOS) at the ASH Annual Meeting
Published: 2021-12-13 (Crawled : 12:30) - globenewswire.com
MREO | $2.64 -0.38% -0.38% 910K
|
Health Technology
|
| O: -6.16%
H: 0.0%
C: 0.0%
phase 1b trial phase 1 syndros biomarkers phase 2b alvelestat
Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
Published: 2021-12-06 (Crawled : 22:00) - biospace.com/
ACAD | $16.82 -1.47% -1.49% 3.5M
|
Health Technology
|
| O: -0.77%
H: 0.0%
C: 0.0%
trial positive results phase 3 syndros topline rett syndrome
Trials Show Hope on the Horizon for Dravet Syndrome, Glioblastoma
Published: 2021-12-06 (Crawled : 19:00) - biospace.com/
KZIA | $0.379 9.47% 8.65% 300K
|
Health Technology
|
| O: -16.26%
H: 0.0%
C: 0.0%
trials trial syndros glioblastoma dravet syndrome
Report of Placebo-Controlled Clinical Trial Evaluating MultiStem® Cell Therapy for Acute Respiratory Distress Syndrome Published in Intensive Care Medicine
Published: 2021-11-30 (Crawled : 12:00) - biospace.com/
ATHX | $0.1018 -40.86% 95M
|
Health Technology
|
| O: 7.62%
H: 0.0%
C: 0.0%
therapy respiratory trial syndros
Curis Announces First Patient Dosed in Phase 1/2 Study of CA-4948 Combination Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Published: 2021-11-08 (Crawled : 15:00) - biospace.com/
CRIS | $14.59 -4.14% -4.32% 10K
|
Health Technology
|
| O: 1.11%
H: 0.0%
C: -5.35%
myeloid leukemia risk phase 1 therapy leukemia syndros ca-4948 acute myeloid leukemia
Keros Therapeutics to Present at the 63rd American Society of Hematology Annual Meeting and Exposition, Including Presenting Additional Data from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes
Published: 2021-11-04 (Crawled : 02:00) - biospace.com/
KROS | $58.345 -1.03% -1.04% 350K
|
Health Technology
|
| O: -1.64%
H: 0.0%
C: 0.0%
ema phase 2 trial syndros
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.